These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK. J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S36-42. PubMed ID: 23519303 [Abstract] [Full Text] [Related]
3. Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK. J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S56-63. PubMed ID: 23519306 [Abstract] [Full Text] [Related]
4. Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less. Katki HA, Gage JC, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Kinney WK. J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S69-77. PubMed ID: 23519308 [Abstract] [Full Text] [Related]
5. Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK. J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S50-5. PubMed ID: 23519305 [Abstract] [Full Text] [Related]
6. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK. J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S78-84. PubMed ID: 23519309 [Abstract] [Full Text] [Related]
7. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK. J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S28-35. PubMed ID: 23519302 [Abstract] [Full Text] [Related]
15. Screening properties of human papillomavirus testing for predicting cervical intraepithelial neoplasia in atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion smears: a prospective study. Dane C, Batmaz G, Dane B, Cetin A. Ann Diagn Pathol; 2009 Apr; 13(2):73-7. PubMed ID: 19302953 [Abstract] [Full Text] [Related]
17. High risk HPV testing in the triage of repeat ASC-US and LSIL. Veijalainen O, Tuomisaari S, Luukkaala T, Mäenpää J. Acta Obstet Gynecol Scand; 2015 Sep; 94(9):931-6. PubMed ID: 26053676 [Abstract] [Full Text] [Related]
18. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A. J Natl Cancer Inst; 2009 Dec 02; 101(23):1612-23. PubMed ID: 19903804 [Abstract] [Full Text] [Related]